Press Release on financial results for Q4FY26 and Year ended March 31, 2026
CORONA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.0 pts less than Nifty Microcap 250 and 4.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Corona Remedies reported strong FY26 results with revenue up 17.3% to ₹1,403.2 Cr and PAT up 33.4% to ₹199.4 Cr (including one-time statutory impact of ₹14.3 Cr post-tax from New Labor Code). Q4FY26 revenue grew 20.2% YoY to ₹353.1 Cr. PAT margins expanded significantly to 14.2% in FY26 vs 12.5% in FY25 (+172 bps), while EBITDA margins improved to 20.9% (+85 bps). The company acquired WOKADINE to enter the ₹648 Cr Povidone Iodine market, relaunched key brands (Fosine R, Menodac, Noklot), and established a dedicated team for the infertility segment. Two brands crossed the ₹100 Cr MAT milestone. Industry ranking improved to 27th from 32nd over three years. EAEU-GMP certification enables entry into Russia and neighboring markets.
Strong margin expansion and robust PAT growth signal operational efficiency gains and brand strength. The strategic WOKADINE acquisition and multi-market expansion support long-term growth, but the one-time labor code impact means underlying PAT growth is slightly lower than headline figures.